FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2936627199> ?p ?o ?g. }

• W2936627199 endingPage "12" @default.
• W2936627199 startingPage "1" @default.
• W2936627199 abstract "Diabetic retinal neurodegeneration, in particular synaptic neurodegeneration of retinal ganglion cells (RGCs) occurring before RGCs apoptosis, may represent the earliest event in the pathogenesis of diabetic retinopathy (DR). Our previous study identified hyperphosphorylated-tau as a critical toxic mediator in diabetic RGCs synaptic neurodegeneration. Thus, therapeutic agents targeting to tau may appear as a promising strategy to arrest the progression of DR. The glucagon-like-peptide 1 receptor (GLP-1R) agonists, including liraglutide, can ameliorate neurodegenerative features in models of Alzheimer's disease and diabetes by decreasing tau hyperphosphorylation in the brain. Liraglutide has also been found to prevent retinal neural apoptosis/loss in diabetic mice. However, whether liraglutide can prevent diabetic synapse degeneration of RGCs, and its neuroprotective role, if any, is due to alleviating retinal tau hyperphosphorylation remain unknown. Here, using a well characterized high-fat diet (HFD)-induced diabetes mouse model, we showed that topical ocular administration of liraglutide reversed hyperphosphorylated tau-triggered RGCs synaptic degeneration in HFD-induced diabetes. The neuroprotective effect of liraglutide on diabetic retinae was abolished when GLP-1R or Akt was inhibited by topically co-administration with a GLP-1R antagonist, exendin-(9–39), or an Akt inhibitor MK2206, respectively. However, knock-down of GSK3β by intravitreal injection of si-GSK3β restored the neuroprotective effects of liraglutide abrogated by Akt inactivation. Thus, our present study demonstrated that liraglutide can arrest hyperphosphorylated tau-triggered retinal neurodegeneration via activation of GLP-1R/Akt/GSK3β signaling. Our results also propose that topical ocular application of liraglutide can be envisaged as a potentially useful strategy for the treatment of retinal tauopathy at the early onset of DR." @default.
• W2936627199 created "2019-04-25" @default.
• W2936627199 creator A5000172750 @default.
• W2936627199 creator A5033314475 @default.
• W2936627199 creator A5034361449 @default.
• W2936627199 creator A5052173587 @default.
• W2936627199 creator A5053868737 @default.
• W2936627199 creator A5059658708 @default.
• W2936627199 creator A5059971691 @default.
• W2936627199 creator A5067584293 @default.
• W2936627199 creator A5077900638 @default.
• W2936627199 creator A5087264224 @default.
• W2936627199 date "2019-07-01" @default.
• W2936627199 modified "2023-09-28" @default.
• W2936627199 title "Topical ocular administration of the GLP-1 receptor agonist liraglutide arrests hyperphosphorylated tau-triggered diabetic retinal neurodegeneration via activation of GLP-1R/Akt/GSK3β signaling" @default.
• W2936627199 cites W1679113345 @default.
• W2936627199 cites W1936579630 @default.
• W2936627199 cites W1955207589 @default.
• W2936627199 cites W1964927978 @default.
• W2936627199 cites W1968276382 @default.
• W2936627199 cites W1971310798 @default.
• W2936627199 cites W1972273243 @default.
• W2936627199 cites W1973774127 @default.
• W2936627199 cites W1976329877 @default.
• W2936627199 cites W1982266611 @default.
• W2936627199 cites W1994623513 @default.
• W2936627199 cites W1999146990 @default.
• W2936627199 cites W2004689357 @default.
• W2936627199 cites W2016593669 @default.
• W2936627199 cites W2030270894 @default.
• W2936627199 cites W2034286717 @default.
• W2936627199 cites W2034632760 @default.
• W2936627199 cites W2050346818 @default.
• W2936627199 cites W2055707729 @default.
• W2936627199 cites W2059127030 @default.
• W2936627199 cites W2060170946 @default.
• W2936627199 cites W2067814945 @default.
• W2936627199 cites W2071472708 @default.
• W2936627199 cites W2075421841 @default.
• W2936627199 cites W2081407214 @default.
• W2936627199 cites W2107054031 @default.
• W2936627199 cites W2107434857 @default.
• W2936627199 cites W2111242088 @default.
• W2936627199 cites W2115977666 @default.
• W2936627199 cites W2146581079 @default.
• W2936627199 cites W2150472993 @default.
• W2936627199 cites W2160241739 @default.
• W2936627199 cites W2167157682 @default.
• W2936627199 cites W2196507910 @default.
• W2936627199 cites W2220065337 @default.
• W2936627199 cites W2231558274 @default.
• W2936627199 cites W2232159238 @default.
• W2936627199 cites W2283812877 @default.
• W2936627199 cites W2342880967 @default.
• W2936627199 cites W2344081812 @default.
• W2936627199 cites W2793413710 @default.
• W2936627199 cites W2901667029 @default.
• W2936627199 cites W4244017022 @default.
• W2936627199 cites W4362221370 @default.
• W2936627199 cites W47608607 @default.
• W2936627199 doi "https://doi.org/10.1016/j.neuropharm.2019.04.018" @default.
• W2936627199 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31015047" @default.
• W2936627199 hasPublicationYear "2019" @default.
• W2936627199 type Work @default.
• W2936627199 sameAs 2936627199 @default.
• W2936627199 citedByCount "25" @default.
• W2936627199 countsByYear W29366271992019 @default.
• W2936627199 countsByYear W29366271992020 @default.
• W2936627199 countsByYear W29366271992021 @default.
• W2936627199 countsByYear W29366271992022 @default.
• W2936627199 countsByYear W29366271992023 @default.
• W2936627199 crossrefType "journal-article" @default.
• W2936627199 hasAuthorship W2936627199A5000172750 @default.
• W2936627199 hasAuthorship W2936627199A5033314475 @default.
• W2936627199 hasAuthorship W2936627199A5034361449 @default.
• W2936627199 hasAuthorship W2936627199A5052173587 @default.
• W2936627199 hasAuthorship W2936627199A5053868737 @default.
• W2936627199 hasAuthorship W2936627199A5059658708 @default.
• W2936627199 hasAuthorship W2936627199A5059971691 @default.
• W2936627199 hasAuthorship W2936627199A5067584293 @default.
• W2936627199 hasAuthorship W2936627199A5077900638 @default.
• W2936627199 hasAuthorship W2936627199A5087264224 @default.
• W2936627199 hasConcept C126322002 @default.
• W2936627199 hasConcept C134018914 @default.
• W2936627199 hasConcept C169760540 @default.
• W2936627199 hasConcept C184235292 @default.
• W2936627199 hasConcept C25498285 @default.
• W2936627199 hasConcept C2776925932 @default.
• W2936627199 hasConcept C2777180221 @default.
• W2936627199 hasConcept C2777739294 @default.
• W2936627199 hasConcept C2778198054 @default.
• W2936627199 hasConcept C2779134260 @default.
• W2936627199 hasConcept C2781308992 @default.
• W2936627199 hasConcept C555293320 @default.
• W2936627199 hasConcept C62478195 @default.
• W2936627199 hasConcept C71924100 @default.
• W2936627199 hasConcept C75217442 @default.
• W2936627199 hasConcept C86803240 @default.

• next